Lidokain Aguettant

Lidocaine Hydrochloride, the active ingredient in Lidokain Aguettant, is a local anesthetic presented as a sterile injectable solution for infiltration, intradermal and intravenous use. It provides reversible nerve blockade for minor surgical, diagnostic and cardiac antiarrhythmic applications. GNH USA supplies Lidokain Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidokain Aguettant is a local anesthetic that acts on peripheral nerves and cardiac tissue to produce temporary loss of sensation or modify electrical conduction. - Minor surgical or diagnostic procedures: provides temporary loss of sensation to facilitate the procedure. - Infiltration anesthesia: enables localized numbness for tissue infiltration during minor surgeries. - Intravenous antiarrhythmic therapy: used under monitoring to manage certain cardiac arrhythmias.

Adverse reactions may occur following administration of Lidokain Aguettant.

Common Side Effects: - Transient burning or stinging at the injection site - Mild dizziness or light‑headedness - Nausea or metallic taste - Localized swelling or erythema

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Cardiac conduction abnormalities such as bradycardia or heart block - Methemoglobinemia - Central nervous system toxicity, including seizures or loss of consciousness

Before using Lidokain Aguettant, consider the following safety measures. - Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular status: avoid in patients with severe heart block or conduction disorders. - Dose limits: adhere to recommended maximum dose to prevent systemic toxicity. - Concurrent CNS depressants: monitor for enhanced sedation when combined with other depressants. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk (category unknown). - Store at ambient temperature: keep in the original container, protect from light and moisture.

Lidokain Aguettant may interact with other medicines; review the following categories.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): additive cardiotoxicity. - Beta‑blockers: increased risk of bradycardia and hypotension. - General anesthetics (e.g., propofol, volatile agents): potentiation of CNS depression. - Monoamine oxidase inhibitors: enhanced local anesthetic toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding at injection sites. - CYP3A4 inhibitors (e.g., erythromycin): can modestly raise plasma lidocaine levels. - Diuretics: may alter electrolyte balance influencing cardiac effects.